"Cervical lymph node staging refers to evaluating regional nodal metastasis from primary cancer of the head and neck. The following article reflects the 8th version of the TNM staging system published by the American Joint Committee on Cancer, which is used for staging starting January 1, 2018 1,2."
"Cervical lymph node staging refers to evaluating regional nodal metastasis from primary cancer of the head and neck. The following article reflects the 8th version of the TNM staging system published by the American Joint Committee on Cancer, which is used for staging starting January 1, 2018 1,2."
"This system applies for epithelial cancers (most commonly squamous cell carcinoma) of most regions of the head and neck, including those of the skin, maxillary sinus, nasal cavity and ethmoid sinus, oral cavity, oropharynx, major salivary glands, hypopharynx, larynx, and unknown primary. Notable exclusions of head and neck cancers are HPV-related oropharyngeal cancer, nasopharyngeal cancer, mucosal melanoma, and thyroid cancers (differentiated, medullary, or anaplastic)."
"NX: nodes cannot be assessed"
"NX: nodes cannot be assessed"
"Clinical nodal status (cN)"
"Pathologic nodal status (pN)"
"N2a: metastasis in single ipsilateral node, >3 cm and ≤6 cm, and ENE(−)"
"N2b: metastasis in multiple ipsilateral nodes, all ≤6 cm, and ENE(−)"
"N2c: metastasis in bilateral or contralateral nodes, all ≤6 cm, and ENE(−)"
"N3a: metastasis in a node, >6 cm, and ENE(−)"
"N3b: metastasis in a node with clinically overt ENE(+) (ENEc)"
"N2a: metastasis in single ipsilateral node, >3 cm and ≤6 cm, and ENE(−); or metastasis in single ipsilateral node, ≤3 cm, and ENE(+)"
"N2b: metastasis in multiple ipsilateral nodes, all ≤6 cm, and ENE(−)"
"N2c: metastasis in bilateral or contralateral nodes, all ≤6 cm, and ENE(−)"
"N3a: metastasis in a node, >6 cm, and ENE(−)"
"N3b: metastasis in single ipsilateral node, >3 cm, and ENE(+); or multiple ipsilateral, contralateral, or bilateral nodes any with ENE(+); or single contralateral node of any size and ENE(+)"
Expected headings
"Clinical nodal status (cN)"
"Pathologic nodal status (pN)"
"This system applies for epithelial cancers (most commonly squamous cell carcinoma) of most regions of the head and neck, including those of the skin, maxillary sinus, nasal cavity and ethmoid sinus, oral cavity, oropharynx, major salivary glands, hypopharynx, larynx, and unknown primary. Notable exclusions of head and neck cancers are HPV-related oropharyngeal cancer, nasopharyngeal cancer, mucosal melanoma, and thyroid cancers (differentiated, medullary, or anaplastic)."
"Clinical determination of ENE requires unambiguous findings on physical examination and supporting radiological evidence; radiologic evidence is insufficient 3. These findings are skin invasion, muscular infiltration, dense tethering/fixation to adjacent structures, or neural invasion with dysfunction involving a cranial nerve, the brachial plexus, the sympathetic trunk, or the phrenic nerve."
"Clinical determination of ENE requires unambiguous findings on physical examination and supporting radiological evidence; radiologic evidence is insufficient 3. These findings are skin invasion, muscular infiltration, dense tethering/fixation to adjacent structures, or neural invasion with dysfunction involving a cranial nerve, the brachial plexus, the sympathetic trunk, or the phrenic nerve."
"N2a: metastasis in single ipsilateral node, >3 cm and ≤6 cm, and ENE(−); or metastasis in single ipsilateral node, ≤3 cm, and ENE(+)"
"N3b: metastasis in single ipsilateral node, >3 cm, and ENE(+); or multiple ipsilateral, contralateral, or bilateral nodes any with ENE(+); or single contralateral node of any size and ENE(+)"
"N3b: metastasis in single ipsilateral node, >3 cm, and ENE(+); or multiple ipsilateral, contralateral, or bilateral nodes any with ENE(+); or single contralateral node of any size and ENE(+)"